Revisiting monoamine oxidase inhibitors for the treatment of depressive disorders: A systematic review and network meta-analysis

Suchting, Robert; Tirumalaraju, Vaishali; Gareeb, Rida; Bockmann, Taya; Dios, Constanza de; Aickareth, Jacob; Pinjari, Omar F.; Soares, Jair C.; Cowen, Philip J.; Selvaraj, Sudhakar

doi:10.1016/j.jad.2021.01.021

Cited by 43 publications

(37 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The MAOIs are included in a group of drugs, commonly referred as thymoleptic drugs, that favorably modifies mood in serious mood disorders and is primarily prescribed for the treatment of clinical depression or mania [23]. The MAO-A inhibitors show efficacy for treating anxiety and depression while the inhibition of MAO-B appears to be effective for prevention and treatment of Parkinson's disease [24,25].…”

Section: Therapeutic Applications Of Mao Inhibitorsmentioning

confidence: 99%

Natural Products Inhibitors of Monoamine Oxidases—Potential New Drug Leads for Neuroprotection, Neurological Disorders, and Neuroblastoma

et al. 2022

View full text Add to dashboard Cite

Monoamine oxidase inhibitors (MAOIs) are an important class of drugs prescribed for treatment of depression and other neurological disorders. Evidence has suggested that patients with atypical depression preferentially respond to natural product MAOIs. This review presents a comprehensive survey of the natural products, predominantly from plant sources, as potential new MAOI drug leads. The psychoactive properties of several traditionally used plants and herbal formulations were attributed to their MAOI constituents. MAO inhibitory constituents may also be responsible for neuroprotective effects of natural products. Different classes of MAOIs were identified from the natural product sources with non-selective as well as selective inhibition of MAO-A and -B. Selective reversible natural product MAOIs may be safer alternatives to the conventional MAOI drugs. Characterization of MAO inhibitory constituents of natural products traditionally used as psychoactive preparations or for treatment of neurological disorders may help in understanding the mechanism of action, optimization of these preparations for desired bioactive properties, and improvement of the therapeutic potential. Potential therapeutic application of natural product MAOIs for treatment of neuroblastoma is also discussed.

show abstract

Section: Therapeutic Applications Of Mao Inhibitorsmentioning

confidence: 99%

Natural Products Inhibitors of Monoamine Oxidases—Potential New Drug Leads for Neuroprotection, Neurological Disorders, and Neuroblastoma

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In addition to being substrates of MAO enzymes, many nitrogen-containing drugs are also MAO inhibitors (Table 11 ) and were among the first agents shown to be efficacious in the treatment of clinical depression (Fernandez and Chen 2007 ; Kalgutkar et al 2001 ; Suchting et al 2021 ). For instance, the therapeutic effects of some antidepressants, hydrazine derivatives (e.g., iproniazid), and tranylcypromine are based on irreversible inhibition of the MAO enzyme and result in the accumulation of sympathetic amines in adrenergic neurons.…”

Section: Examples Of Reactions Resulting In the Formation Of Toxic Me...mentioning

confidence: 99%

Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions

Rendić¹,

Crouch

Guengerich

2022

Arch Toxicol

View full text Add to dashboard Cite

This is an overview of the metabolic reactions of drugs, natural products, physiological compounds, and other (general) chemicals catalyzed by flavin monooxygenase (FMO), monoamine oxidase (MAO), NAD(P)H quinone oxidoreductase (NQO), and molybdenum hydroxylase enzymes (aldehyde oxidase (AOX) and xanthine oxidoreductase (XOR)), including roles as substrates, inducers, and inhibitors of the enzymes. The metabolism and bioactivation of selected examples of each group (i.e., drugs, “general chemicals,” natural products, and physiological compounds) are discussed. We identified a higher fraction of bioactivation reactions for FMO enzymes compared to other enzymes, predominately involving drugs and general chemicals. With MAO enzymes, physiological compounds predominate as substrates, and some products lead to unwanted side effects or illness. AOX and XOR enzymes are molybdenum hydroxylases that catalyze the oxidation of various heteroaromatic rings and aldehydes and the reduction of a number of different functional groups. While neither of these two enzymes contributes substantially to the metabolism of currently marketed drugs, AOX has become a frequently encountered route of metabolism among drug discovery programs in the past 10–15 years. XOR has even less of a role in the metabolism of clinical drugs and preclinical drug candidates than AOX, likely due to narrower substrate specificity.

show abstract

“…Serotonin is produced in the human body through biosynthesis from the essential amino acid tryptophan (Fitzpatrick, 1999), and broken down by monoamine oxidase to generate 5-hydroxyindoleacetic acid. As such, monoamine oxidase inhibitors and other compounds that increase serotonin concentration have been used to treat depression (Suchting et al, 2021).…”

Section: Chemical Contextmentioning

confidence: 99%

Crystal structure of serotonin

Naeem¹,

Chadeayne²,

Golen³

et al. 2022

Acta Cryst E

View full text Add to dashboard Cite

The title compound, serotonin or 5-hydroxytryptamine (5-HT) [systematic name: 3-(2-aminoethyl)-1H-indol-5-ol], C10H12N2O, has one molecule in the asymmetric unit. The conformation of the ethylamino side chain is gauche–gauche [Ca—Ca—Cm—Cm and Ca—Cm—Cm—N (a = aromatic, m = methylene) torsion angles = −64.2 (3) and −61.9 (2)°, respectively]. In the crystal, the molecules are linked into a three-dimensional network by N—H...O and O—H...N hydrogen bonds.

show abstract

Revisiting monoamine oxidase inhibitors for the treatment of depressive disorders: A systematic review and network meta-analysis

Cited by 43 publications

References 28 publications

Natural Products Inhibitors of Monoamine Oxidases—Potential New Drug Leads for Neuroprotection, Neurological Disorders, and Neuroblastoma

Natural Products Inhibitors of Monoamine Oxidases—Potential New Drug Leads for Neuroprotection, Neurological Disorders, and Neuroblastoma

Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions

Crystal structure of serotonin

Contact Info

Product

Resources

About